Results 71 to 80 of about 14,494 (232)

Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials

International Journal of Infectious Diseases, 2020
Background: Tenofovir disoproxil fumarate (TDF) can cause renal and bone toxicity, which is associated with high plasma tenofovir concentrations in antiretroviral treatment of HIV-1 infected patients.
Xingbao Tao, Yanqiu Lu, Yihong Zhou, Lvlang Zhang, Yaokai Chen   +4 more
doaj   +1 more source

Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities [PDF]

, 2016
Renal toxicity in a 73 year old man using tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) is described. Reduced renal reserve, a higher exposure to co-medications and co-morbidities can present a challenge when assessing the risks ...
Barber, TJ, Girometti, N, Jones, R, Levy, J, McCormack, S, Sullivan, A   +5 more
core   +1 more source

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B [PDF]

, 2023
Antiviral therapy; IncidenceTerapia antiviral; IncidenciaTeràpia antiviral; IncidènciaBackground & Aims Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).
Agarwal, Kosh, Ahn, Sang-Hoon, Buti Ferret, Maria, Chan, Henry Lik Yuen, Lim, Young-Suk, Ning, Qin, Seto, Wai-Kay   +6 more
core   +1 more source

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV

Journal of Renal and Hepatic Disorders, 2018
Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections.
Nicole Marie Lioufas, Alan Street, Paul Champion de Crespigny, Stephen G Holt   +3 more
doaj   +1 more source

Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV

Viruses, 2023
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens.
María F. Rombini, Diego Cecchini, Sofía Diana Menendez, Liliana Calanni, Rosana Cuini, Elena Obieta, María M. Greco, Fabricio Morales, Laura Morganti, Claudia Migazzi, Yasmin El Kozah, Pablo Parenti, Isabel Cassetti, on behalf of the COVIDARE Study Team   +13 more
doaj   +1 more source

Phosphoramidates and phosphonamidates (ProTides) with antiviral activity [PDF]

, 2018
Following the first report on the nucleoside phosphoramidate (ProTide) prodrug approach in 1990 by Chris McGuigan, the extensive investigation of ProTide technology has begun in many laboratories.
Arbelo RC, Cha A, Chen C-L, Fabrizio Pertusati, Jonckers THM, Magdalena Slusarczyk, Matthews SJ., Michaela Serpi, Saboulard D, Vig R   +9 more
core   +2 more sources

Compare HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate or tenofovir alafenamide fumarate

, 2022
Abstract Background/purpose: Clinical relapse occurred majorly within the first six months after stopping tenofovir disoproxil fumarate (TDF) in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. However, the incidence and relapse pattern in patients stopping Tenofovir alafenamide fumarate (TAF), a prodrug of tenofovir ...
CH Chen, Wen-Juei Jeng, Tsung-Hui Hu, Yen-Chun Liu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Rong-Nan Chien   +7 more
openaire   +1 more source

4CPS-060 Prescription analysis of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in a third level hospital [PDF]

Section 4: Clinical Pharmacy Services, 2020
Background and importance Tenofovir alafenamide (TAF) is a novel tenofovir prodrug, recently entering the market for HIV infections. TAF results in higher intracellular concentrations of the active metabolite tenofovir diphosphate compared with tenofovir disoproxil fumarate (TDF), allowing for much lower doses of TAF versus TDF.
A Caraffa, A Colicchio, L Gasperoni, G Selvetti, I Tommasini, E Zuccarini, M Mancini   +6 more
openaire   +1 more source

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study

AIDS Research and Therapy, 2021
Background Antiretrovirals, including tenofovir, can suppress human immunodeficiency virus (HIV) infection but cannot completely eradicate it. Patients with HIV infection are administered antiretroviral drugs over a long term; thus, managing consequent ...
Mahoko Ikeda, Yoshitaka Wakabayashi, Koh Okamoto, Shintaro Yanagimoto, Shu Okugawa, Kyoji Moriya   +5 more
doaj   +1 more source